Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study by Pengo, V et al.
THROMBOSIS AND HEMOSTASIS
Incidence of a first thromboembolic event in asymptomatic carriers of high-risk
antiphospholipid antibody profile: a multicenter prospective study
Vittorio Pengo,1 Amelia Ruffatti,2 Cristina Legnani,3 Sophie Testa,4 Tiziana Fierro,5 Francesco Marongiu,6
Valeria De Micheli,7 Paolo Gresele,5 Marta Tonello,2 Angelo Ghirarduzzi,8 Elisa Bison,1 Gentian Denas,1
Alessandra Banzato,1 Seena Padayattil Jose,1 and Sabino Iliceto1
Departments of 1Clinical Cardiology and 2Rheumatology, University Hospital, Padova, Italy; 3Department of Angiology and Blood Coagulation Marino Golinelli,
University Hospital, Bologna, Italy; 4District Hospital, Cremona, Italy; 5Internal and Vascular Medicine, University Hospital, Perugia, Italy; 6Internal Medicine,
University Hospital, Cagliari, Italy; 7Transfusion Medicine, District Hospital, Merate, Italy; and 8Angiology Unit, Department of Internal Medicine, Santa Maria
Nuova Hospital, Reggio Emilia, Italy
Persistent antiphospholipid (aPL) antibod-
ies are occasionally found in subjects
without prior history of thromboembolic
events (TEs), raising the dilemma of
whether to initiate or not a primary throm-
boprophylaxis. A first TE is considered
rare in aPL carriers, but previous studies
did not consider the aPL profile nor was
the test positivity confirmed in a refer-
ence laboratory. In this study, 104 sub-
jects with high-risk aPL profile (positive
lupus anticoagulant, anticardiolipin, and
anti-2–glycoprotein I antibodies, triple
positivity) confirmed in a reference labo-
ratory, were followed up for a mean of
4.5 years. There were 25 first TEs (5.3%
per year): the cumulative incidence after
10 years was 37.1% (95% confidence inter-
val [CI], 19.9%-54.3%). On multivariate
analysis, male sex (hazard ratio  4.4;
95% CI, 1.5-13.1, P  .007) and risk fac-
tors for venous thromboembolism (haz-
ard ratio  3.3; 95% CI, 1.3-8.5, P  .01)
were independent predictors for TEs. As-
pirin did not significantly affect the inci-
dence of TE. In conclusion, the occur-
rence of a first TE in carriers of high-risk
aPL profile is considerable; it is more
frequent among male subjects and in the
presence of additional risk factors for
venous TE. These data can help in the
decision to initiate primary thrombopro-
phylaxis in these subjects. (Blood. 2011;
118(17):4714-4718)
Introduction
It is now widely recognized that multiple positivity in tests
exploring the presence of antiphospholipid (aPL) antibodies (lupus
anticoagulant [LA], anticardiolipin [aCL], and anti-2–glycoprotein I
[anti-2GPI] antibodies) is associated with thromboembolic events
(TEs) more frequently than single test positivity.1-5 Notably, triple
positivity (all 3 tests positive) is associated with thrombosis and
identifies high-risk patients with aPL syndrome (APS).6,7 In this respect,
the finding of a healthy person carrying aPL triple positivity poses the
problem of actual risk of TEs and raises the dilemma of whether a
primary prophylaxis with antithrombotic drugs should be initiated.
Here, we describe a cohort of patients with triple-positive tests that were
prospectively followed in Italian Thrombosis Centers, and assess TEs
and their predictors.
Methods
Study design and population
This study considered patients positive for all 3 tests exploring aPL (LA,
aCL, and anti-2GPI antibodies) on 2 occasions at least 12 weeks apart
without exhibiting the clinical features of APS. Recruited subjects were
seen by the center physician in an outpatient setting once a year or earlier
according to their clinical status or if discharged from the hospital. No
long-term anticoagulant treatment was prescribed, and all the subjects
received short-term thromboprophylaxis with once-daily low molecular
weight heparin in high-risk for TE scenarios (surgery or prolonged
immobilization).
To confirm triple positivity for aPL and to validate the laboratory
diagnosis, plasma from patients of each center was retested in a reference
laboratory (Padua Thrombosis Center). Final inclusion in the cohort
required confirmation of LA positivity as well as aCL and anti-2GPI
antibody positivity (values in the upper 99th percentile of 40 healthy
subjects) for the same isotype. The predominant isotype was considered M
when IgM aCL value expressed as MPL units exceeded the IgG aCL value
(expressed as GPL units). Patients positive for LA and aCL before
anti-2GPI ELISA was available had the test performed subsequently on
the first original stored plasma. All subjects were informed about the study
and gave signed consent about the treatment of their data in accordance with
the Declaration of Helsinki. The study was approved by the local ethics
committee of each Thrombosis Center.
Data collection at laboratory diagnosis
Centers were asked to provide demographic, laboratory, and clinical data
for each patient. TEs and pregnancy morbidity before laboratory diagnosis
were excluded on the basis of patient interview and available hospital
records.
Information about the presence of associated autoimmune diseases
(systemic lupus erythematosus [SLE] or other connective tissue disease)
and the presence of additional risk factors for thrombosis was also
collected. Assessed arterial risk factors were: diabetes mellitus, hyperten-
sion, hypercholesterolemia, obesity, smoking habit, and family history.
Assessed venous risk factors were: oral estroprogestinic treatment, preg-
nancy, malignancy, family history, and thrombophilia (antithrombin, pro-
tein C, or protein S; factor V Leiden; prothrombin G20210A mutation;
hyperhomocysteinemia, high factor VIII levels).
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Laboratory tests
Methods and results for laboratory diagnosis refer to tests performed in the
reference laboratory. Lupus anticoagulant was determined according to
updated guidelines of the International Society on Thrombosis and Hemo-
stasis8 using a diluted Russell viper venom time kit by Instrumentation
Laboratory; results of mixing tests are expressed as the ratio of diluted
Russell viper venom time of 1:1 mixing of patient and normal pooled
plasma, divided by diluted Russell viper venom time of pooled normal
plasma (normal value, 1.2).9 aCL and anti–human 2GPI antibodies were
measured by home-made ELISA as previously described,10 following the
proposals of the Standardization Group of the European Forum on anti-PL
antibodies.11,12 aCL ELISA and anti-2GPI ELISA were considered positive
when values exceeded the cut-off value calculated using the 99th percentile
of 40 normal age- and sex-matched controls. Laboratory data for ELISA
tests are reported as predominant IgG or IgM isotypes.
Outcome events
Reports for objectively diagnosed TEs during follow-up had to include
type, site, and the status of antithrombotic treatment at the time of event.
Venous thromboembolism (VTE) was diagnosed by compression
ultrasonography or venography in case of deep vein thrombosis, and spiral
tomography, ventilation-perfusion lung scan, or pulmonary angiography in
case of pulmonary embolism. Intracerebral thrombosis was assessed by
computed tomographic scanning, magnetic resonance imaging, or angiogra-
phy; retinal thrombosis was diagnosed by ophthalmologic examination.
Peripheral- or mesenteric-artery thrombosis was documented by arteriogra-
phy or at the surgery table. Small-vessel thrombosis was evaluated by
appropriate imaging study or histopathology in the absence of inflammation
in the vessel wall. Acute myocardial infarction was diagnosed in the
presence of a typical clinical presentation associated with typical electrocar-
diographic features and elevated cardiac enzymes (CK-MB or troponins I or
T). Stoke/transient ischemic attack was defined according to standard
definitions (transient ischemic attack was considered for analysis only if
cerebral imaging confirmed cerebral ischemia). Major bleeding was defined
as: fatal bleeding causing death, clinically overt bleeding associated with a
fall in hemoglobin level of  20 g/L in 24 hours, and/or requiring
nonplanned transfusion of  2 units of packed red blood cells or whole
blood; intracranial bleeding (documented by imaging), retroperitoneal
bleeding, intraocular bleeding causing blindness, joint hemorrhage, or need
for surgery or angiographic intervention to stop hemorrhage. All other
bleeding events not matching the criteria for major bleeding were consid-
ered minor bleeding. The causes of death were obtained from clinical or
autopsy reports and/or death certificates.
Statistics
Descriptive statistics are reported as appropriate: categorical data are
expressed as frequencies (percentage); continuous data are reported as
mean SD. Kaplan-Meier survival analysis was used to determine the
cumulative incidence of TEs at follow-up. Cox regression survival analysis
was used to detect possible predictors of thromboembolism among the
demographic factors, associated autoimmune diseases, aCL isotype, arterial
and venous risk factors, and aspirin treatment at the time of event. Statistical
significance was considered for P .05. All analyses were performed using
SPSS (Rel. 17.0.1. 2008).
Results
Of the considered 110 patients, 6 were excluded from the study
(3 because of history of pregnancy loss compatible with APS and
3 for not meeting the inclusion criteria after specimen test in the
reference laboratory). Demographic and clinical characteristics of
104 confirmed triple-positive carriers are depicted in Table 1. Mean
age was 45 years, and 79% were female. Reasons for aPL testing
were frequently an occasionally found prolonged activated partial
thromboplastin time or an autoimmune disorder. In the study
cohort, SLE or other autoimmune diseases were present in 47% of
cases, and risk factors for arterial and venous thrombosis were
present in approximately one-third of subjects. IgG was the
prevalent isotype in 83% of cases. During a total follow-up of
469 years, there were 25 TEs (5.3% per year). The cumulative
incidence of TEs was 9.8% (95% confidence interval [CI],
3.7%-15.9%) after 2 years, 27.3% (95% CI, 17.1%-37.5%) after
5 years, and 37.1% (95% CI, 19.9%-54.3%) after 10 years
(Figure 1).
Details of the 25 patients who developed a TE are shown in
Table 2. There were 12 arterial and 11 venous TEs, 1 thrombosis of
the right atrium, and 1 renal thrombotic microangiopathy. Other
Figure 1. Cumulative incidence of TEs in the follow-up period of 104 carriers of
triple positivity for aPL antibody tests.
Table 1. Demographic and clinical characteristics
Characteristics Value
No. 104
Age, y (mean  SD) 45  15
Female, no. (%) 82 (79)
IgG isotype, no. (%) 86 (83)
dRVVT mixing (mean  SD) 1.78  0.5
IgG aCL, GPL units (mean  SD) 102  91
IgG a2GPI, units (mean  SD) 123  154
IgM isotype, no. (%)
dRVVT mixing 18 (17)
IgM aCL, GPL units (mean  SD) 1.42  0.3
IgM a2GPI, units (mean  SD) 81  58
Reason for initial testing, no. (%)
Prolonged aPTT 55 (53)
Autoimmune disorder 39 (37)
Family history for thrombosis 4 (4)
Migraine 2 (2)
Autoimmune disorders, no. (%)
SLE 14 (13)
Other 35 (34)
Risk for arterial thrombosis* no. (%) 34 (33)
Risk for venous thrombosis† no. (%) 30 (29)
dRVVT indicates diluted Russell viper venom time; and aPTT, activated partial
thromboplastin time.
*Considered risk factors for arterial thrombosis: diabetes mellitus, hypertension,
hypercholesterolemia, obesity, smoking habit, and family history.
†Considered risk factor for venous thrombosis: recent surgical intervention,
perioperative immobilization, oral estroprogestinic treatment, pregnancy, malignancy,
family history, thrombophilia, and previous VTE.
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possible TEs not included among endpoints were superficial
thrombophlebitis in 2 subjects and a case of Addison disease, the
most frequent endocrine disorder in APS. Two subjects died (one of
lymphoma and the other of leukemia). Pregnancy morbidity during
the follow-up period occurred in 7 of the 8 females who became
pregnant (3 were early abortion, 2 were eclampsia with premature
birth, and 2 were fetal deaths).
The 25 patients with TEs were compared with the 79 controls
who did not have this complication. On multivariate analysis of
considered variables for TEs (Table 3), male sex (hazard ra-
tio  4.4; 95% CI, 1.5-13.1, P  .007) and the presence of factors
predisposing to VTE (hazard ratio 3.3; 95% CI, 1.3-8.5, P .01)
were found to be independent predictors for clinical events. Aspirin
prophylaxis was close to significance in reducing events on
univariate analysis but did not achieve statistical significance on
multivariate analysis (hazard ratio 0.5; 95% CI, 0.2-1.5, P  .2).
The same holds true when considering the reduction in arterial TEs.
Discussion
The clinical course in persons with high-risk aPL antibody profile
(triple positivity) is not known, casting a shadow on the need for
primary prophylaxis to avoid TEs. To address this issue, we
evaluated a group of persons followed at Italian Thrombosis
Centers, that were homogeneous in terms of aPL positivity (plasma
specimens from all the subjects were tested in a reference
laboratory). We previously described a group of patients with triple
positivity and APS7 whose characteristics in terms of age, sex,
prevalence of IgG isotype, and associated autoimmune diseases are
similar to the group reported in this study. Results show a
considerable incidence of TEs during the follow-up period with
values of 9.8% after 2 years and a constant increase thereafter with
an incidence of 37.1% after 10 years (annualized incidence is
5.3%). On the basis of a limited number of retrospective and
Table 2. Details of subjects affected by thromboembolism in the follow-up period
Patient
no. Age, y Sex Ig isotype (G or M) Time lag,* y Primary prophylaxis Type of event
1 13 Female G 5.4 ASA Stroke†
2 61 Male G 0.9 — Stroke†
3 24 Female G 18.4 ASA Renal thrombotic microangiopathy
4 56 Female G 2.5 — Proximal DVT
5 54 Male G 4 ASA Proximal DVT
6 25 Female G 1.8 — Stroke†
7 43 Female G 1.5 — Proximal DVT
8 30 Female G 2.6 — PE
9 33 Female G 2 — Stroke†
10 54 Male G 4 — Stroke†
11 22 Male M 1.2 — Proximal DVT  PE
12 57 Female G 2.1 — Myocardial infarction
13 48 Male G 2.4 — Stroke†
14 44 Female G 3.1 — Proximal DVT  PE
15 38 Male G 1.8 — Proximal DVT
16 50 Male G 1 — Proximal DVT  PE
17 40 Male G 3 — PE
18 65 Female G 9 — TIA†
19 22 Female G 1.7 — Right atrial thrombosis
20 57 Female G 5 ASA TIA†
21 41 Female M 11.5 ASA Retinal artery thrombosis
22 55 Female G 4.8 — Proximal DVT
23 45 Female M 2 ASA Proximal DVT
24 53 Female G 3.2 ASA Stroke†
25 31 Female G 2.8 — Stroke†
— indicates no primary prophylaxis; ASA, aspirin 100 mg 4 times a day; DVT, deep vein thrombosis; PE, pulmonary embolism; and TIA, transient ischemic attack.
*Time interval from laboratory finding to the thromboembolic event.
†All the clinical events had a pertinent area of ischemia at cerebral imaging.
Table 3. Risk factors for thrombosis in the follow-up period
Hazard ratio
Risk factor Thrombosis (N  25) Controls (N  79) Univariate 95% CI Multivariate 95% CI
Age, y (mean  SD) 42.4  14.2 45.3  14.7 1.0 0.97-1.02 — —
Male sex no. (%) 8 (32) 14 (18) 3.3 1.4-8.0 4.4 1.5-13.1
aCL titre, GPL units (mean  SD) 95  85 84  91 1.0 0.99-1.01 — —
G isotype, no. (%) 22 (88) 64 (81) 1.7 0.5-5.6 — —
Associated autoimmune diseases, no.(%) 10 (40) 39 (49) 0.6 0.2-1.1 — —
Arterial risk factors, no. (%) 8 (32) 26 (33) 0.9 0.4-2.2 — —
Venous risk factors, no. (%) 10 (40) 12 (15) 2.7 1.2-6.3 3.3 1.3-8.5
Aspirin prophylaxis, no. (%) 7 (28) 30 (38) 0.4 0.1-1.1 — —
— indicates not significant.
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prospective studies that predominantly include SLE patients,
asymptomatic aPL-positive patients have a 0% to 3.8% annual
thrombosis risk.13
We report in Figure 2 the annual rate ( 0.4%) of first
cardiovascular event (including VTE) in normal white population
at 35 to 55 years of age,14 that (1.36%) of 125 single aPL positive
carriers with a mean age of 41 years (data taken by a recently
published study by our group),15 and that (5.3%) of triple-positive
carriers of this study (mean age, 45 years). Annual rate in a cohort
of SLE patients half of whom had aPL was 2.9 per 100 patient-
years.16 Hence, because less than half of our cohort had autoim-
mune disorders, the higher incidence of TEs recorded in this study
may be related to the selection of high-risk aPL-positive popula-
tion. Likewise, in patients with APS and triple positivity,7 TEs were
equally distributed among arterial and venous circulation. Some
patients in this study were treated with aspirin for primary
thromboprophylaxis, behavior that did not lead to a significant
reduction of events. To our knowledge, only one prospective
clinical trial addresses the question of primary prophylaxis in
asymptomatic aPL carriers.17 The Antiphospholipid Antibody Ace-
tylsalicylic Acid study was a randomized, double-blind, placebo-
controlled clinical trial in asymptomatic patients with persistently
positive aPL comparing the efficacy of aspirin 81 mg daily versus
placebo for the prevention of thrombotic complications. The study
was terminated earlier for low rate of events and showed that in
patients with persistently positive aPL, aspirin was no more
effective than placebo. On the other hand, other observational
studies show that aspirin treatment is beneficial for primary
thromboprophylaxis.18,19 In all these studies, the aPL profile of
carriers is not well documented or confirmed by a reference
laboratory: in the study by Giron-Gonzalez et al,19 few subjects
were positive for LA, whereas most were positive in IgM aCL, an
isotype showing weak or no association with TEs.20,21 Notably, in a
recent prospective study15 assessing the risk factors for a first
thrombotic event in aPL antibody carriers, most of whom with
autoimmune diseases, it was found that hypertension and LA
positivity are independent risk factors for thrombosis, and primary
thromboprophylaxis (aspirin in most cases) should probably be
limited to high thromboembolic risk clinical scenarios. It is now
clear that LA positivity is associated with TEs.22 However, it is
mandatory to know the complete aPL profile of patients/carriers as
in our hands the sole positivity for LA is not associated with
thrombosis,6 or with clinical manifestations of APS.23 Similar
conclusions were drawn from the Leiden thrombophilia case-
control study,24 where LA positivity in the absence of anti-2GPI or
antiprothrombin antibodies was not associated with an augmented
risk for deep vein thrombosis (odds ratio 1.3; 95% CI, 0.3-6.0).
It must be underlined here that, in triple-positive patients, LA
potency is strong and the titer of aCL (mostly IgG) and anti-2GPI
antibodies is high.7,23
Most carriers of triple positivity in this study (64%) were not
prescribed antithrombotic prophylaxis, and the remaining were
given low-dose aspirin. However, aspirin use did not result in a
significant reduction either of total TEs or of the sole arterial
thromboembolism. Thus, in the presence of high-risk aPL profile
(triple positivity), aspirin is not effective in primary prevention and
is significantly less effective than vitamin K antagonists in the
secondary prevention.7 Searching for additional risk factors for a
first TE may be crucial in decision-making. Male sex and the
presence of risk factors for VTE were found to be independent risk
factors for a first TE in this study. That male sex is related to a
higher risk for recurrence of VTE among patients with unprovoked
deep vein thrombosis is not new.25 Thus, because aspirin does not
significantly affect the rate of a first TE among high-risk patients,
the use of anti–vitamin K or new oral anticoagulants in the near
future should be considered, particularly if the subject is male with
other risk factors for VTE. Of the 18 patients treated with
hydroxychloroquine, 2 (11%) had a first TE in the follow-up
period. A potential protective role of this drug is possible and may
explain the risk reduction for thrombosis in patients with associated
autoimmune disorders. Larger clinical trials are definitely needed
to test these hypotheses.
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